Resultado da Busca
Há 3 dias · For example, targeted therapies such as radiotherapy, vasculature targeting agents, and immunogenic chemotherapy can improve immune checkpoint blockade response in animal models. Combining various immunotherapies such as PD1 and CTLA4 inhibitors can enhance anti-tumor response leading to durable responses.
Há 4 dias · Therapies targeting CD19 (refs. 101 , 175 , 176 ), CD20 (refs. 11 , 177 , 178 ), CD38 (ref. 179 ) and BCMA 180 , 181 for cancers of the B cell lineage represent the most successful examples of ...
Há 22 horas · Overcome resistance: A strategic combination of medicines can hinder the tumours’ ability to develop resistance, and potentially enhance patient outcomes. Enhance treatment response: Combination therapy has the potential to enhance cancer cell death, and lead to deeper and more durable responses compared to monotherapy.
Há 1 dia · Targeted therapies. Complementary: All-trans retinoic acid (ATRA) α; Bortezomib α; Dasatinib α; Erlotinib α; Everolimus α; Ibrutinib α; Imatinib α; Nilotinib α; Rituximab α; Trastuzumab α; Immunomodulators. Complementary: Filgrastim α; Lenalidomide α; Nivolumab α; Pegfilgrastim α; Thalidomide α
Há 3 dias · Breast cancer is a cancer that develops from breast tissue. [7] Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. [1] In those with distant spread of the disease, there may be bone pain ...
- 685,000 (global, 2020)
- Five-year survival rate ≈85% (US, UK)
Há 3 dias · Targeted Therapies 201: What's New and on the Horizon. Authors: Stephen Liu, MD; Kristen A. Marrone, MD; Ben P. Levy, MD; Elaine Shum, MD; Joshua Reuss, MD CME / ABIM MOC / CE Released: 3/31/2023 THIS ACTIVITY HAS EXPIRED FOR CREDIT; Valid for credit through: 3/31/2024, 11:59 PM EST
Há 2 dias · Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Yunfei Chen. Yanmei Xu ...
